Inorganic Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 30, 2025
A
series
of
structurally
related
bistridentate
heteroleptic
Ru(II)
polypyridyl
complexes,
[RuII(ttpy)(8-HQLS/N/O)]+
(Ru1-Ru3),
were
synthesized,
where
ttpy
=
p-tolyl
terpyridine
and
8-HQLS/N/O
are
monoanionic
N^N^O-donor
tridentate
ligands
(8-HQLX),
derived
from
8-hydroxyquinoline
(8-HQ),
namely,
8-HQLS
2-(2'-benzothiazole)-8-hydroxyquinoline,
8-HQLN
2-(2'-benzimidazole)-8-hydroxyquinoline,
8-HQLO
2-(2'-benzoxazole)-8-hydroxyquinoline.
The
electronic
structures
these
rigid
systematically
tuned
by
varying
the
noncoordinating
heteroatoms
(S,
O,
NH)
in
five-membered
heterocyclic
ring,
impacting
properties,
redox
potentials,
excited-state
lifetime/dynamics,
deactivation
pathways
photophysical
behavior
corresponding
complexes.
Notably,
[RuII(ttpy)(8HQLN)]+
(Ru2)
exhibited
an
lifetime
(τ
>
1
ns
CH3CN
at
RT)
surpassing
that
homoleptic
complex
[Ru(ttpy)2]2+
∼
0.62
ns),
despite
its
more
distorted
octahedral
geometry.
These
complexes
(Ru1-Ru3)
showed
extended
lifetimes
compared
to
their
counterpart
Ru4.
displayed
absorption
red
region,
which
is
favorable
for
phototherapeutic
applications.
Their
relative
singlet
oxygen
(1O2)
quantum
yields
(ΦΔ)
ranged
0.03
0.10.
Given
reasonable
1O2
generation
ability,
demonstrated
potential
as
photocatalysts
organic
substrates,
evidenced
effectiveness
photooxidation
PPh3
Ph3P=O
a
model
reaction.
Journal of the American Chemical Society,
Journal Year:
2025,
Volume and Issue:
147(9), P. 7161 - 7181
Published: Feb. 20, 2025
Photocatalytic
cancer
therapy
(PCT)
has
emerged
as
a
cutting-edge
anticancer
mechanism
of
action,
harnessing
light
energy
to
mediate
the
catalytic
oxidation
intracellular
substrates.
PCT
is
significant
current
importance
due
its
potential
address
limitations
conventional
chemotherapy,
particularly
drug
resistance
and
side
effects.
This
approach
offers
noninvasive,
targeted
treatment
option
by
utilizing
metal-based
photocatalysts
induce
redox
metabolic
disorders
within
cells.
The
disrupt
cell
metabolism
converting
NADH/NAD(P)H
NAD+/NAD(P)+
via
photoredox
processes,
altering
NAD+/NADH
or
NAD(P)+/NAD(P)H
ratios,
which
are
crucial
for
cellular
metabolism.
Ir(III),
Ru(II),
Re(I),
Os(II)
demonstrated
promising
efficacy.
Despite
these
developments,
gaps
remain
in
literature
translating
this
new
into
clinical
trials.
Perspective
critically
examines
developments
research
area
provides
future
directions
designing
efficient
PCT.
Chemical Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
NIR
activatable,
self-degradable
iridium(
iii
)–dithiocarbamate–cyanine
complexes
were
synthesized.
They
act
as
type
I
and
II
PDT
agent
at
ultra-low-power
irradiation
high
laser
power,
they
exhibited
photoactivated
chemotherapy
(PACT).
Journal of Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
68(9), P. 9741 - 9754
Published: April 28, 2025
Photocleavable
protecting
groups
hold
great
promise
in
photopharmacology
to
control
the
release
of
bioactive
molecules
from
their
caged
precursors
within
specific
subcellular
compartments.
Herein,
we
describe
a
series
photocages
based
on
COUPY
scaffold,
incorporating
chlorambucil
(CLB)
and
4-phenylbutyric
acid
(4-PBA)
as
payloads
that
can
be
efficiently
activated
with
visible
light.
Confocal
microscopy
confirmed
preferential
accumulation
CLB
4-PBA
N-hexyl
mitochondria,
which
exhibited
remarkable
phototoxicity
against
cancer
cells
upon
green-yellow
light
irradiation,
IC50
values
nanomolar
range.
This
effect
was
attributed
synergistic
mechanism
involving
photorelease
intrinsic
photogeneration
Type
I
II
ROS
by
scaffold
mitochondria.
Thus,
COUPY-caged
derivatives
underscore
potential
COUPY-caging
versatile
platform
develop
innovative
light-activated
agents
operating
simultaneously
through
photodynamic
therapy
photoactivated
chemotherapy.
Inorganic Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 30, 2025
A
series
of
structurally
related
bistridentate
heteroleptic
Ru(II)
polypyridyl
complexes,
[RuII(ttpy)(8-HQLS/N/O)]+
(Ru1-Ru3),
were
synthesized,
where
ttpy
=
p-tolyl
terpyridine
and
8-HQLS/N/O
are
monoanionic
N^N^O-donor
tridentate
ligands
(8-HQLX),
derived
from
8-hydroxyquinoline
(8-HQ),
namely,
8-HQLS
2-(2'-benzothiazole)-8-hydroxyquinoline,
8-HQLN
2-(2'-benzimidazole)-8-hydroxyquinoline,
8-HQLO
2-(2'-benzoxazole)-8-hydroxyquinoline.
The
electronic
structures
these
rigid
systematically
tuned
by
varying
the
noncoordinating
heteroatoms
(S,
O,
NH)
in
five-membered
heterocyclic
ring,
impacting
properties,
redox
potentials,
excited-state
lifetime/dynamics,
deactivation
pathways
photophysical
behavior
corresponding
complexes.
Notably,
[RuII(ttpy)(8HQLN)]+
(Ru2)
exhibited
an
lifetime
(τ
>
1
ns
CH3CN
at
RT)
surpassing
that
homoleptic
complex
[Ru(ttpy)2]2+
∼
0.62
ns),
despite
its
more
distorted
octahedral
geometry.
These
complexes
(Ru1-Ru3)
showed
extended
lifetimes
compared
to
their
counterpart
Ru4.
displayed
absorption
red
region,
which
is
favorable
for
phototherapeutic
applications.
Their
relative
singlet
oxygen
(1O2)
quantum
yields
(ΦΔ)
ranged
0.03
0.10.
Given
reasonable
1O2
generation
ability,
demonstrated
potential
as
photocatalysts
organic
substrates,
evidenced
effectiveness
photooxidation
PPh3
Ph3P=O
a
model
reaction.